ArticleCancer immunology, immunotherapy : CII2024

MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity.

Young Jin Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.